A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION). Article

Kotecha, Rupesh, Odia, Yazmin, Chen, Zhijian et al. (2025). A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION). . JOURNAL OF CLINICAL ONCOLOGY, 43(16_suppl), 2022-2022. 10.1200/jco.2025.43.16_suppl.2022

cited authors

  • Kotecha, Rupesh; Odia, Yazmin; Chen, Zhijian; Starosciak, Amy K; Hodgson, Lydia; La Rosa, Alonso; Pimentel, Antoinette M; Perche, Dilanis; Hall, Matthew D; Press, Robert H; Ahluwalia, Manmeet Singh; Mehta, Minesh P

authors

publication date

  • June 1, 2025

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6.1 Pharmaceuticals
  • 6.2 Cellular and gene therapies
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Health Disparities
  • Minority Health
  • Neurosciences
  • Orphan Drug
  • Radiation Oncology
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 2022

end page

  • 2022

volume

  • 43

issue

  • 16_suppl